Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Nov 10;11(11):CD010338.
doi: 10.1002/14651858.CD010338.pub3.

Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders

Sujoy Ray  1 , Amita Ray
Affiliations
Meta-Analysis

Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders

Sujoy Ray et al. Cochrane Database Syst Rev. .

Abstract

Background: Heavy menstrual bleeding without an organic lesion is mainly due to an imbalance of the various hormones which have a regulatory effect on the menstrual cycle. Another cause of heavy menstrual bleeding with no pelvic pathology, is the presence of an acquired or inherited bleeding disorder. The haemostatic system has a central role in controlling the amount and the duration of menstrual bleeding, thus abnormally prolonged or profuse bleeding does occur in most women affected by bleeding disorders. Whereas irregular, pre-menarchal or post-menopausal uterine bleeding is unusual in inherited or acquired haemorrhagic disorders, severe acute bleeding and heavy menstrual bleeding at menarche and chronic heavy menstrual bleeding during the entire reproductive life are common. This is an update of a previously published Cochrane Review.

Objectives: To determine the efficacy and safety of non-surgical interventions versus each other, placebo or no treatment for reducing menstrual blood loss in women with bleeding disorders.

Search methods: We searched the Cochrane Cystic Fibrosis Haemoglobinopathies Trials Register (25 August 2016), Embase (May 2013), LILACS (February 2013) and the WHO International Clinical Trial registry (February 2013).

Selection criteria: Randomised controlled studies of non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women of reproductive age suffering from a congenital or acquired bleeding disorder.

Data collection and analysis: Two authors independently assessed studies for inclusion, extracted data and assessed the risk of bias.

Main results: Three cross-over studies, with 175 women were included in the review. All three studies had an unclear risk of bias with regards to trial design and overall, the quality of evidence generated was judged to be poor.Two of the studies (n = 59) compared desmopressin (1-deamino-8-D-arginine vasopressin) with placebo. Menstrual blood loss was the primary outcome for both of these studies. Neither study found clear evidence of a difference between groups. The first of these reported a mean difference in menstrual blood loss in the desmopressin versus placebo group of 21.20 mL (95% confidence interval -19.00 to 61.50)The second study reported that even though there was an improvement of pictorial bleeding assessment chart scores with desmopressin and placebo when compared to pretreatment assessment, there was no clear evidence of difference in these scores when the two were compared to each other (results presented graphically, P = 0.51). The data from these studies could not be combined.The third study (n = 116) compared desmopressin with tranexamic acid (n = 116). This study found a decrease in pictorial bleeding assessment chart scores after both treatments as compared to baseline. The decrease in these scores was greater for tranexamic acid than for desmopressin, with a mean difference of 41.6 mL (95% confidence interval 19.6 to 63) (P < 0.0002).In relation to adverse events, across two studies, there was no clear evidence of a difference when placebo was compared to desmopressin, risk ratio 1.17 (95% confidence interval 0.41 to 3.34) . The same was also true when desmopressin was compared to tranexamic acid, risk ratio 1.17 (95% confidence interval 0.41 to 3.34).Only the study that compared desmopressin to tranexamic acid assessed quality of life. However, we are unable to present any data from this study, since no differences in this outcome between the two intervention groups were reported.

Authors' conclusions: Evidence from randomised controlled studies on the effect of desmopressin when compared to placebo in reducing menstrual blood loss is very limited and inconclusive. Two studies, each with a very limited number of participants, have shown uncertain effects in menstrual blood loss and adverse effects. A non-randomised comparison in one of the studies points to the value of combining desmopressin and tranexamic acid, which needs to be tested in a formal randomised controlled study comparison.When tranexamic acid was compared to desmopressin, a single study showed a reduction in menstrual blood loss with tranexamic acid use compared to desmopressin.There is a need to evaluate non-surgical methods for treating of menorrhagia in women with bleeding disorders through randomised controlled studies. Such methods would be more acceptable than surgery for women wishing to retain their fertility. Given that women may need to use these treatments throughout their entire reproductive life, long-term side-effects should be evaluated.

PubMed Disclaimer

Conflict of interest statement

Both authors: none known.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
4
4
Forest plot of comparison: 1 DDAVP Vs Placebo, outcome: 1.1 Adverse effects.
5
5
Forest plot of comparison: 2 Desmopressin versus Tranaxemic Acid, outcome: 2.1 Adverse effects.
1.1
1.1. Analysis
Comparison 1 Desmopressin versus placebo, Outcome 1 Adverse effects.
2.1
2.1. Analysis
Comparison 2 Desmopressin versus tranexamic acid, Outcome 1 Adverse effects.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Edlund 2002 {published data only}
    1. Edlund M, Blombäck M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagulation and Fibrinolysis 2002;13(3):225‐31. - PubMed
Kadir 2000 {published data only}
    1. Kadir RA, Economides DL, Lee CA. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a prospective randomized placebo‐controlled cross‐over study [abstract]. Haemophilia 2000;6(4):243. - PubMed
    1. Kadir RA, Lee CA, Economides DL. DDVAP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a prospective randomized placebo‐controlled crossover study. XVI FIGO World Congress of O & G. 2000; Vol. Abstract book 2:93. [CENTRAL: 363397; CRS: 5500050000000469]
    1. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo‐controlled crossover study. Haemophilia 2002;8(6):787‐93. - PubMed
Kouides 2009 {published data only}
    1. Kouides PA, Byams RV, Philipp CS, Stein SF, Heit JA, et al. Multisite management study of menorrhagia with abnormal laboratory haemostasis: a prospective crossover study of intranasal desmopressin and oral tranexamic acid. British Journal of Haematology 2009;145(2):212‐20. - PubMed

References to studies excluded from this review

Ammesse 2005 {published data only}
    1. Amesse LS, Pfaff‐Amesse T, Leonardi R, Uddin D, French JA 2nd. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD‐associated menorrhagia: a single‐institution study. Journal of Pediatric Hematology/Oncology 2005;27(7):21‐5. - PubMed
Chi 2011 {published data only}
    1. Chi C, Huq FY, Kadir RA. Levonorgestrel‐releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long‐term follow‐up. Contraception 2011;83(3):242‐7. - PubMed
Choudry 2009 {published data only}
    1. Choudry A, Malik A, Choudry H, Bangish N, Hayat N. Effectiveness and safety of Levonorgestrel Releasing Intrauterine System in treatment of menorrhagia secondary to oral anticoagulations and chronic liver disease. Rawal Medical Journal 2009;34(2):187‐90.
Halimeh 2012 {published data only}
    1. Halimeh S. Menorrhagia and bleeding disorders in adolescent females. Hamostaseologie 2012;32(1):45‐50. - PubMed
Kingman 2004 {published data only}
    1. Curtis R. The use of levonorgestrel‐releasing intrauterine system for the treatment of menorrhagia in women with inherited bleeding disorders. BJOG: an International Journal of Obstetrics and Gynaecology 2006;113(2):248‐9. - PubMed
    1. Kingman CE, Kadir RA, Lee CA, Economides DL. The use of levonorgestrel‐releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG: an International Journal of Obstetrics and Gynaecology 2004;111(12):1425‐8. - PubMed
Lukes 2008 {published data only}
    1. Lukes AS, Kouides PA, Moore KA. Tranexamic acid: A novel oral formulation for the treatment of heavy menstrual bleeding. Women's Health 2011;7(2):151‐8. - PubMed
Rodeghiero 2008 {published data only}
    1. Rodeghiero F. Management of menorrhagia in women with inherited bleeding disorders:General principles and use of desmopressin. Haemophilia 2008;14(1):21‐30. - PubMed
Rose 2008 {published data only}
    1. Rose SS, Faiz A, Miller CH, Saidi P, Philipp CS. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction. Haemophilia 2008;14(3):571‐8. - PubMed
Schaedel 2005 {published data only}
    1. Schaedel ZE, Dolan G, Powell MC. The use of the levonorgestrel‐releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. American Journal of Obstetrics and Gynecology 2005;193(4):1361‐3. - PubMed

Additional references

Cai 2005
    1. Cai K, Gierman TM, Hotta J, Stenland CJ, Lee DC, Pifat DY, et al. Ensuring the biologic safety of plasma‐derived therapeutic proteins. Detection, inactivation, and removal of pathogens. Biodrugs 2005;19(2):79–96. - PMC - PubMed
CDC 1998
    1. Centers for Disease Control and Prevention (CDC). Health related quality of life and activity limitation – eight states. Morbidity and Mortality Weekly Report 1998; Vol. 47:134‐140. - PubMed
Chalmers 2007
    1. Chalmers EA, Brown SA, Keeling D, Liesner R, Richards M, Stirling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007;13(2):149–55. - PubMed
Chamberlain 2003
    1. Chamberlain P, Mire‐Sluis AR. An overview of scientific and regulatory issues for the immunogenicity of biological products. Developmental Biology 2003;112:3–11. - PubMed
Chen 2008
    1. Chen YC, Chao TY, Cheng SN, Hu SH, Liu JY. Prevalence of von Willebrand disease in women with iron deficiency anaemia and menorrhagia in Taiwan. Haemophilia 2008;14(4):768‐74. - PubMed
Clarke 1995
    1. Clarke A, Black N, Rowe P, Mott S, Howie K. Indications for and outcomes of total abdominal hysterectomy for benign disease: a prospective cohort study. British Journal of Obstetrics and Gynaecology 1995;102(6):11–20. - PubMed
Cole 1971
    1. Cole S, Billewicz W, Thomson A. Sources of variation in menstrual blood loss. Journal of Obstetrics and Gynaecology of the British Commonwealth 1971;78(10):939–49. - PubMed
Deligdisch 2000
    1. Deligdisch l. The 1999 long course on pathology of the uterine corpus and cervix. Modern Pathology 2000;13(3):285–94. - PubMed
Demers 2006
    1. Demers C, Derzko C, David M, Douglas J, Society of Obstetricians and Gynaecologists of Canada. Gynaecological and obstetric management of women with inherited bleeding disorders. International Journal of Gynaecology and Obstetrics 2006;95(1):75‐87. - PubMed
Douglas 1997
    1. Douglas JT, Shaw J. High dose desmopressin in bleeding disorders. European Journal of Anaesthesiology 1997;14 Suppl:v‐vi. - PubMed
Dunn 2000
    1. Dunn AL, Powers JR, Ribeiro MJ, Rickles FR, Abshire TC. Adverse events during use of intranasal desmopressin acetate for haemophilia A and von Willebrand disease: a case report and review of 40 patients. Haemophilia 2000;6(1):11‐4. - PubMed
Edlund 1996
    1. Edlund M, Blombäck M, Schoultz B, Andersson O. On the value of menorrhagia as a predictor for coagulation disorders. American Journal of Hematology 1996;53(4):234‐8. - PubMed
El‐Hemaidi 2007
    1. El‐Hemaidi I, Gharaibeh A, Shehata H. Menorrhagia and bleeding disorders. Current Opinion in Obstetrics and Gynecology 2007;19(6):513‐20. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9. - PubMed
Falcone 1994
    1. Falcone T, Desjardins C, Bourque J. Dysfunctional uterine bleeding in adolescents. Journal of Reproductive Medicine 1994;39(10):761‐4. - PubMed
Farquhar 2009
    1. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD000154.pub2] - DOI - PubMed
FDA 2011
    1. U.S. Food, Drug Administration (FDA). Highlights of prescribing information: Lysteda™ (tranexamic acid) tablets. Reference ID: 2928912. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022430s002lbl.pdf (accessed 13 March 2014).
Fraser 1983
    1. Fraser IS, McCarron G, Markham R, Robinson M, Smyth E. Long‐term treatment of menorrhagia with mefenamic acid. Obstetrics and Gynecology 1983;61(1):3‐6. - PubMed
Fraser 1985
    1. Fraser IS, McCarron G, Markham R, Resta T. Blood and total fluid content of menstrual discharge. Obstetrics and Gynecology 1985;65(2):194–8. - PubMed
Fredrick 2008
    1. Ofosu FA, Freedman J, Semple JW. Plasma‐derived biological medicines used to promote haemostasis. Thrombosis and Haemostasis 2008;99(5):851–62. - PubMed
Garay 2006
    1. Garay RP, Chiavaroli C, Hannaert P. Therapeutic efficacy and mechanism of action of ethamsylate, a long‐standing haemostatic agent. American Journal of Therapeutics 2006;13(3):236‐47. - PubMed
Gath 1982
    1. Gath D, Cooper P, Day A. Hysterectomy and psychiatric disorder: I. Levels of psychiatric morbidity before and after hysterectomy. International Journal of Psychiatry 1982;140:335–40. - PubMed
Halberg 1966
    1. Hallberg L, Högdahl AM, Nilsson L, Rybo G. Menstrual blood loss‐‐a population study. Variation at different ages and attempts to define normality. Acta Obstetricia et Gynecologica Scandinavica 1966;45(3):320–51. - PubMed
Hardman 2001
    1. Hardman JG, Limbird LE, Gilman AG. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th Edition. McGraw‐Hill, 2001.
Hassan 2005
    1. Hassan AA, Kroll AH. Acquired Disorders of Platelet Function. Hematology / The Education Program of the American Society of Hematology 2005;1:403‐8. - PubMed
Haynes 1977
    1. Haynes P, Hodgson H, Anderson A, Turnbull A. Measurement of menstrual blood loss in patients complaining of menorrhagia. British Journal of Obstetrics and Gynaecology 1977;84(10):763–8. - PubMed
Higgins 2011a
    1. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011b
    1. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higham 1990
    1. Higham JM, O’Brien PM, Shaw RW. Assessment of menstrual blood loss using a pictorial chart. British Journal of Obstetrics and Gynaecology 1990;97(8):734‐9. - PubMed
James 2006
    1. James AH, Ragini MV, Picozzi VJ. Bleeding disorders in premenopausal women: (another) public health crisis for hematology?. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2006;2006(1):474‐85. - PubMed
Jayasinghe 2005
    1. Jayasinghe Y, Moore P, Donath S, Campbell J, Monagle P, Grover S. Bleeding disorders in teenagers presenting with menorrhagia. Australian and New Zealand Journal of Obstetrics and Gynaecology 2005;45(5):439‐43. - PubMed
Jenkin 1980
    1. Jenkin G. Review: The Mechanism of Action of Danazol, a Novel Steroid Derivative. Australian and New Zealand Journal of Obstetrics and Gynaecology 1980;20(2):113–8. - PubMed
Kadir 2002
    1. Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomised placebo‐controlled crossover study. Haemophilia 2002;8(6):787‐93. - PubMed
Kadir 2010
    1. Kadir RA, EdlundM, Mackensen S. The impact of menstrual disorders on quality of life in women with inherited bleeding disorders. Haemophilia 2010;16(5):832‐9. - PubMed
Kadira 1998
    1. Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Frequency of inherited bleeding disorders in women with menorrhagia. Lancet 1998;351(9101):485‐9. - PubMed
Klein 2004
    1. Klein HG. Pathogen inactivation technology:cleansing the blood supply. Journal of Internal Medicine 2004;257(3):224–37. - PubMed
Lethaby 2000
    1. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD000249] - DOI - PubMed
Mannuci 1997
    1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 Years. Blood 1997;90(7):2515‐21. - PubMed
Mercorio 2003
    1. Mercorio F, Simone R, Carlo C. Effectiveness and mechanism of action of desmopressin in the treatment of copper intrauterine device‐related menorrhagia: a pilot study. Human Reproduction 2003;18(11):2319‐22. - PubMed
Miller 2011
    1. Miller CH, Philipp CS, Stein SF, Kouides PA, Lukes AS, Heit JA, et al. The spectrum of haemostatic characteristics of women with unexplained menorrhagia. Haemophilia. 2011;17(1):e223‐9. - PubMed
NICE Guidelines 2007
    1. National Institute for Health and Clinical Excellence (NICE). Heavy menstrual bleeding. Clinical Guideline 2007. www.ncbi.nlm.nih.gov/books/NBK56536/pdf/TOC.pdf (accessed 20 October 2011).
NZ Guidelines Group 1999
    1. New Zealand Guidelines Group. Working Party for Guidelines for the Management of Heavy Menstrual Bleeding. An evidence‐based guideline for the management of heavy menstrual bleeding. New Zealand Medical Journal 1999;112(1088):174‐7. - PubMed
Oeheler 2003
    1. Oehler MK, Rees MC. Menorrhagia: an update. Acta Obstetrica et Gynecologica Scandinavica 2003;82(5):405‐22. - PubMed
Philipp 2010
    1. Philipp CS. Platelet disorders in adolescents. Journal of Pediatric and Adolescent Gynecology 2010;23(6 Suppl):11‐4. - PubMed
Phillip 2003
    1. Philipp CS, Dilley A, Miller CH, Evatt B, Baranwal A, Schwartz R, et al. Platelet functional defects in women with unexplained menorrhagia. Journal of Thrombosis and Haemostasis 2003;1(3):477‐84. - PubMed
Pipe 2008
    1. Pipe SW. Recombinant clotting factors. Thrombosis and Haemostasis 2008;99(5):840–50. - PubMed
Radcliff 1997
    1. Radloff LS. The CES‐D scale: a self report depression scale for research in the general population. Applied Psychological Measurement 1997; Vol. 1:385‐41.
Reid 2005
    1. Reid PC, Virtanen‐Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. British Journal of Obstetrics and Gynecology 2005;112(8):8‐14. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Ruta 1995
    1. Ruta DA, Garratt AM, Chadha YC, Flett GM, Hall MH, Russell IT. Assessment of patients with menorrhagia: how valid is a structured clinical history as a measure of health status?. Quality of Life Research 1995; Vol. 4:33‐40. - PubMed
Saxena 2003
    1. Saxena R, Gupta M, Gupta PK, Kashyap R, Choudhry VP, Bhargava M. Inherited bleeding disorders in Indian women with menorrhagia. Haemophilia 2003;9(2):193‐6. - PubMed
Schelkens 2003
    1. Schellekens H. Immunogenicity of therapeutic proteins. Nephrology, Dialysis, Transplantation 2003;18(7):1257–9. - PubMed
Shankar 2004
    1. Shankar M, Lee CA, Sabin CA, Economides DL, Kadir RA. von Willebrand disease in women with menorrhagia: a systematic review. BJOG: an International Journal of Obstetrics & Gynaecology 2004;111(7):734‐40. - PubMed
Shetty 2011
    1. Shetty S, Kasatkar P, Ghosh K. Pathophysiology of acquired von Willebrand disease: a concise review. European Journal of Haematology 2011;87(2):99‐106. - PubMed
van Eijkeren 1990
    1. Eijkeren MA, Christiaens GC, Haspels AA, Sixma JJ. Measured menstrual blood loss in women with a bleeding disorder or using oral anticoagulant therapy. American Journal of Obstetrics and Gynecology 1990;162(5):1261‐3. - PubMed
van Eijkeren 1992
    1. Eijkeren MA, Christiaens GC, Geuze HJ, Haspels AA, Sixma JJ. Effects of mefenamic acid on menstrual haemostasis in essential menorrhagia. American Journal of Obstetrics and Gynecology 1992;166(5):1419‐28. - PubMed
Vessey 1992
    1. Vessey MP, Villard‐Mackintosh L, McPherson K, Coulter A, Yeates D. The epidemiology of hysterectomy: findings in a large cohort study. British Journal of Obstetrics & Gynaecology 1992;99(5):402‐7. - PubMed
Von Depka 2002
    1. Depka M. NovoSeven: mode of action and use in acquired haemophilia. Intensive Care Medicine 2002;28(2 Suppl):s222‐7. - PubMed
Ware 1993
    1. Ware JE, Snow K, Kosinski M, Gandek B. SF‐36 HealthSurvey Manual and Interpretation Guide. The Health Institute, Boston, MA 1993.

References to other published versions of this review

Ray 2014
    1. Ray S, Ray A. Non‐surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD010338.pub2] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources